Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001493152-24-033487
Filing Date
2024-08-22
Accepted
2024-08-22 06:07:19
Documents
13
Period of Report
2024-08-15
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-ka.htm   iXBRL 8-K/A 47950
  Complete submission text file 0001493152-24-033487.txt   227575

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE prph-20240815.xsd EX-101.SCH 3027
3 XBRL LABEL FILE prph-20240815_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE prph-20240815_pre.xml EX-101.PRE 22367
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-ka_htm.xml XML 4509
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

EIN.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 000-21617 | Film No.: 241230065
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)